Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    symvivo
Previous Study | Return to List | Next Study

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04334980
Recruitment Status : Not yet recruiting
First Posted : April 6, 2020
Last Update Posted : September 14, 2020
Sponsor:
Information provided by (Responsible Party):
Symvivo Corporation

Brief Summary:
Protocol bacTRL-Spike-1 will be the first-in-human study of bacTRL-Spike, and the first-in-human use of orally delivered bacTRL. Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1A), 3 billion (Group 2A) or 10 billion (Group 3A) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: bacTRL-Spike Phase 1

Detailed Description:

Protocol bacTRL-Spike-1 will be the first-in-human study of bacTRL-Spike, and the first-in-human use of orally delivered bacTRL. The trial is designed to evaluate the safety and tolerability of orally delivered bacTRL-Spike vaccine in healthy adults.

Total anticipated enrollment is n=12. The distribution of the sample size will be as follows:

  • Group 1 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 1 billion colony forming units (cfu) of Bifidobacterium longum (B. longum);
  • Group 2 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 3 billion cfu of B. longum;
  • Group 3 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 10 billion cfu of B. longum;
  • Group 4 (n=3): Single Data and Safety Monitoring Board (DSMB)-defined dose of bacTRL-Spike among subjects 56 years of age and older.

The planned trial duration is 18 months.

Each participant will remain in the trial for 12-13 months, including a screening phase of up to 28 days, intervention phase of 1 day and follow-up phase of 12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults
Estimated Study Start Date : October 2020
Estimated Primary Completion Date : December 30, 2021
Estimated Study Completion Date : February 28, 2022

Arm Intervention/treatment
Experimental: bacTRL-Spike
  • Group 1 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 1 billion colony forming units (cfu) of Bifidobacterium longum (B. longum);
  • Group 2 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 3 billion cfu of B. longum;
  • Group 3 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 10 billion cfu of B. longum;
  • Group 4 (n=3): Single Data and Safety Monitoring Board (DSMB)-defined dose of bacTRL-Spike among subjects 56 years of age and older.
Biological: bacTRL-Spike
Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1), 3 billion (Group 2) or 10 billion (Group 3) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.




Primary Outcome Measures :
  1. Frequency of Adverse Events [ Time Frame: Up to12 months post-vaccination ]
    Adverse events (specifically including incidence of gastrointestinal-associated events) following administration of oral bacTRL-Spike


Secondary Outcome Measures :
  1. Immune response against SARS-CoV-2 Spike protein [ Time Frame: Baseline (pre-vaccination), and 1, 3 and 12 months post-vaccination ]
    Antibody against SARS-CoV-2 Spike protein

  2. Incidence of COVID-19 infection [ Time Frame: Up to 12 months post-vaccination ]
    Incidence and clinical phenotype of confirmed and probable COVID-19 infection among vaccinated participants, based on current public health definitions

  3. bacTRL-Spike in stool post-vaccination [ Time Frame: Days 8, 15, 22, and 1 and 3 months post-vaccination ]
    Isolation of viable bacTRL-Spike from stool post-vaccination

  4. Immunity against SARS-CoV-2 [ Time Frame: Up to 12 months post-vaccination ]
    Collection of biological samples for future studies to understand immunity against SARS-CoV-2.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

INCLUSION CRITERIA

  1. Age 18 years inclusive at time of enrollment and older;
  2. Capable to and does provide written informed consent;
  3. Able to understand and agrees to comply with planned study procedures and be available for all study visits;
  4. Body Mass Index 18-32 kg/square meter, inclusive, at screening;
  5. Male or non-pregnant, non-breastfeeding females who agree to comply with applicable contraceptive requirements of the protocol (see Table 1: Acceptable Contraceptive Methods.) Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to initiation of vaccination;
  6. Pulse no greater than 100 beats per minute;
  7. Systolic blood pressure (BP) is 85 to 150 mmHg, inclusive;
  8. Clinical screening laboratory evaluations:

    • Absolute neutrophil count (ANC) ≥1500 cells/mm3
    • Hemoglobin ≥12.0 g/dL for men and ≥11.0 g/dL for women
    • Platelet count ≥120,000/mm3
    • Creatinine clearance (CrCl) >80 mL/min ); Refer to the calculator located on the Frontier Science and Technology Research Foundation (FSTRF) website (at https://www.frontierscience.org/): Calculated Creatinine Clearance - Cockcroft-Gault Equation (Adult).
    • Aspartate aminotransferase (AST) <1.25 x upper limit of normal (ULN)
    • Alanine aminotransferase (ALT) <1.25 x ULN
    • Alkaline phosphatase <2.0 x ULN
    • Total bilirubin <1.1 x ULN
    • Lipase <1.1 x ULN
    • Prothrombin time (PT) <1.1 x ULN
    • Partial thromboplastin time (PTT) <1.1 x ULN
    • CRP < 2.0 x ULN
  9. Agree to have samples stored for secondary research related to coronaviruses.

EXCLUSION CRITERIA

  1. Positive pregnancy test either at screening or just prior to vaccine administration.
  2. Female participant who is breastfeeding or plans to breastfeed from the time of the study vaccination through 3 months after the study vaccination.
  3. Has acute or chronic inflammatory condition of the gastrointestinal tract including, but not limited to, Crohn's disease, ulcerative colitis, gastritis, proctitis, or any other inflammatory bowel disorder.
  4. Has any medical disease, history, or behavior that may predispose to more severe COVID-19 infection, including hypertension, diabetes, current vaping and/or smoking, history of chronic smoking within the prior year (average of at least one cigarette per day or more), or body mass index of greater than 32; stable hypertension controlled with a stable dose of medication is permitted.
  5. Has any medical disease or condition that, in the opinion of the site PI or appropriate sub-investigator, precludes study participation (including but not limited to acute, subacute, intermittent or chronic medical disease or condition that would place the participant at an unacceptable risk of injury, render the participant unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the participant's successful completion of this trial.)
  6. Presence of self-reported or medically documented significant medical or psychiatric condition(s).

    Significant medical or psychiatric conditions include but are not limited to:

    • Respiratory disease (e.g., chronic obstructive pulmonary disease, asthma) requiring daily medications currently or any treatment of respiratory disease exacerbations (e.g., asthma exacerbation) in the last 5 years.
    • Excluded asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and short acting beta agonists, theophylline, ipratropium, biologics.
    • Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult.
    • Neurological or neurodevelopmental conditions (e.g., migraines, epilepsy, stroke, seizures in the last 3 years, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis).Ongoing malignancy or recent diagnosis of malignancy in the last five years excluding basal cell and squamous cell carcinoma of the skin, which are allowed.
    • An autoimmune disease, including hypothyroidism without a defined non-autoimmune cause, localized or history of psoriasis.
    • An immunodeficiency of any cause or are immune-suppressed.
  7. Has an acute illness, as determined by the site PI or appropriate sub-investigator, with or without fever (oral temperature >38.0 degrees Celsius [100.4 degrees Fahrenheit]) within 72 hours prior to study vaccination administration.
  8. Has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) types 1 or 2 antibodies at screening.
  9. Has participated in another investigational study involving any investigational product (study drug, biologic or device) within 60 days, or 5 half-lives, whichever is longer, before study vaccine administration.
  10. Currently enrolled in or plans to participate in another clinical trial with an investigational agent (including licensed or unlicensed vaccine, drug, biologic, device, blood product, or medication) that will be received during the trial period.
  11. Has a history of hypersensitivity or severe allergic reaction (e.g., anaphylaxis, generalized urticaria, angioedema, other significant reaction) to any previous licensed or unlicensed vaccines.
  12. Chronic use (more than 14 continuous days) or anticipated use within the next 6 months of any medications that may be associated with impaired immune responsiveness. Including, but not limited to the following excluded drugs: systemic corticosteroids exceeding 10 mg/day of prednisone equivalent, allergy injections, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or other similar or toxic drugs during the preceding 6-month period prior to vaccine administration (Day 1). The use of low dose topical, ophthalmic, inhaled and intranasal steroid preparations will be permitted.
  13. Received immunoglobulins and/or any blood or blood products within the 4 months before study vaccine administration or at any time during the study.
  14. Has any blood dyscrasias or significant disorder of coagulation.
  15. Has any chronic liver disease, including fatty liver.
  16. Has a history of alcohol or drug abuse or tests positive for drugs of abuse at screening.
  17. Received or plans to receive a licensed, live vaccine within 4 weeks before or after each vaccination.
  18. Received or plans to receive a licensed, inactivated vaccine within 2 weeks before or after each vaccination.
  19. Receipt of any other SARS-CoV-2/COVID-19, or other experimental coronavirus vaccine at any time prior to or during the study.
  20. Known current or previous laboratory-confirmed SARS CoV-1 OR SARS-CoV-2/COVID-19 infection as documented by a positive PCR test from a nasal swab.
  21. Known close contact of anyone with laboratory-confirmed SARS-CoV-2/COVID-19 infection within 2 weeks prior to vaccine administration.
  22. Has traveled outside Australia for any duration within 30 days before study vaccination.
  23. Currently working in occupation with high risk of exposure to SARS-CoV-2 (e.g., health care worker, emergency response personnel).
  24. Allergy to BOTH amoxicillin (or any penicillin derivative) AND erythromycin
  25. Household contact, including neonates up to the age of 28 days, with any medical condition or taking medications that may result in immunosuppression.
  26. The participant must agree to refrain from donating blood or plasma during the study.
  27. Excluded medications (summarized): Excluded asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and short acting beta agonists, theophylline, ipratropium, biologics; Excluded immunosuppressive drugs: systemic corticosteroids exceeding 10 mg/day of prednisone equivalent, allergy injections, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or other similar or toxic drugs during the preceding 6-month period prior to vaccine administration (Day 1); Excluded other medications - current use of any antibiotics, probiotic supplements, H2 blockers or proton pump inhibitors within 7 days prior to vaccination and any anticipated use for 7 days post vaccination.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04334980


Contacts
Layout table for location contacts
Contact: Alexander Graves, PhD, MBA (604) 428-7474 bd@symvivo.com
Contact: Michelle Jones, RN, M.Sc., MBA 604-428-7474 bd@symvivo.com

Locations
Layout table for location information
Australia, Victoria
Nucleus Network Pty Ltd (Trading as Centre for Clinical Studies)
Melbourne, Victoria, Australia, 3004
Contact: Paul Griffin, MD       p.griffin@nucleusnetworks.com.au   
Principal Investigator: Paul Griffin, MD         
Sponsors and Collaborators
Symvivo Corporation
Investigators
Layout table for investigator information
Study Director: Eric L Sievers, MD Chief Medical Officer
Principal Investigator: Paul Griffin, FRACP FRCPA FACTM FIML AFACHSM Principal Investigator
Layout table for additonal information
Responsible Party: Symvivo Corporation
ClinicalTrials.gov Identifier: NCT04334980    
Other Study ID Numbers: bacTRL-Spike-1
First Posted: April 6, 2020    Key Record Dates
Last Update Posted: September 14, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No